Contract facts
FederalNo full NAICS 325412 intel page yet. Browse NAICS intelligence
FY26 PHARMACEUTICALS TAKEDA APRIL-SEPTEMBER is a federal award for Fmc Fort Worth held by Takeda Pharmaceuticals America, Inc. Estimated value $549K ($549K obligated). Current period of performance ends Sep 30, 2026. Last award drew 1 bidder. Place of performance: FORT WORTH TX.
FY26 PHARMACEUTICALS TAKEDA APRIL-SEPTEMBER
Recompete timing
PublicCurrent PoP ends Sep 30, 2026 (40 days remaining). Agencies typically plan 12–18 months ahead — at 1.3 months out, that window is already open. The buying decision is likely already in motion.
Incumbent footprint
Public recordTakeda Pharmaceuticals America, Inc — $6.5M obligated across 96 awards (firm-wide, all agencies) · lead buyer Department of Justice (DOJ).
Query this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP →
Frequently asked questions
What is contract 15B50926F00000076?
15B50926F00000076 (Fy26 pharmaceuticals TAKEDA april-september) is a Fmc Fort Worth award with a potential value of $549K, currently held by Takeda Pharmaceuticals America, Inc. Figures are USASpending-sourced public-record facts plus SCOUT recompete analysis.
Which office awarded 15B50926F00000076?
Fmc Fort Worth awarded 15B50926F00000076 to Takeda Pharmaceuticals America, Inc (potential $549K).
Who is the incumbent on 15B50926F00000076?
Takeda Pharmaceuticals America, Inc is the incumbent with $6.5M across 96 related awards in SCOUT’s public footprint. The current period of performance ends Sep 30, 2026.
When does Takeda Pharmaceuticals America, Inc’s 15B50926F00000076 come up for recompete?
SCOUT tracks a period-of-performance end of Sep 30, 2026. Actual solicitation timing can shift with extensions, bridges, or consolidations.
Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows.